WHITE PAPER:
Barriers to Precision Medicine
From Quantity Not Sufficient to Quality Care
Precision medicine offers patients chemotherapy or targeted therapy. Targeted therapy is vital for improving survival, but determination of eligibility depends on molecular testing, which can be challenging due to low abundance of quality tissue. This white paper explores the need for more sensitive molecular methods outside of the NGS paradigm, particularly for low-quality or quantity samples.
This paper highlights why pursuing highly sensitive molecular methods beyond NGS is not just a scientific endeavor but a clinical necessity.
In this white paper you’ll gain insights on the:
- Importance of precise molecular profiling for patients.
- Challenges of targeted therapy due to limitations of current NGS-based molecular tests.
- Benefit of implementing sensitive and robust molecular tumor profiling methods.
Complete the form to receive the exclusive white paper on the challenges of QNS in molecular tumor profiling.
Download Now
Complete the form to receive the exclusive white paper on the challenges of QNS in molecular tumor profiling.